Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Zhang C, Lv GQ, Yu XM, Gu YL, Li JP, Du LF, Zhou P (2011) Current evidence on the relationship between HRAS1 polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. doi:10.​1007/​s10549-011-1344-2
2.
Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, Thompson J, Infante-Rivard C, Guyatt G (2009) How to use an article about genetic association: A: background concepts. JAMA 301:74–81PubMedCrossRef
3.
Attia J, Thakkinstian A, D’Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297–303PubMedCrossRef
4.
Boccia S, De Feo E, Gallì P, Gianfagna F, Amore R, Ricciardi G (2010) A systematic review evaluating the methodological aspects of meta-analyses of genetic association studies in cancer research. Eur J Epidemiol 25:765–775PubMedCrossRef
5.
Metadata
Title
Limited evidence supported the association of HRAS1 polymorphism with breast cancer risk
Authors
Xiujun Zhang
Mengchun Jia
Publication date
01-07-2011
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1407-4

Other articles of this Issue 2/2011

Breast Cancer Research and Treatment 2/2011 Go to the issue

Epidemiology

Improved survival of patients with primary distant metastatic breast cancer in the period of 1995–2008. A nationwide population-based study in the Netherlands

Preclinical study

Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection

Clinical Trial

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

Clinical trial

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

Preclinical study

Distinct function of androgen receptor coactivator ARA70α and ARA70β in mammary gland development, and in breast cancer

Epidemiology

Breast cancers in U.S. residing Indian-Pakistani versus non-Hispanic White women: comparative analysis of clinical-pathologic features, treatment, and survival
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits